Poxvirus‐based vaccine candidates for cancer, AIDS, and other infectious diseases

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Journal of Leukocyte Biology

• Publication date

  1995-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jlb.58.1.1PMID 7616101
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunological and virological characterization of improved construction of recombinant vaccinia virus expressing rinderpest virus hemagglutinin

  2005cited by this paper
• Immunotherapy of tumor-bearing mice utilizing virus help

  2004cited by this paper
• A Prime-Boost Approach to HIV Preventive Vaccine Using a Recombinant Canarypox Virus Expressing Glycoprotein 160 (MN) followed by a Recombinant Glycoprotein 160 (MN/LAI)

  1995cited by this paper
• Poxvirus-based vectors as vaccine candidates.

  1995cited by this paper
• A phase III randomized, doúble‐blind, multiinstitutional trial of vaccinia melanoma oncolysate‐active specific immunotherapy for patients with stage II melanoma

  1995cited by this paper
• A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.

  1995cited by this paper
• Live Attenuated Vaccinia and Other Poxviruses as Delivery Systems: Public Health Issues

  1995cited by this paper
• HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques

  1995cited by this paper
• Avipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens.

  1994cited by this paper
• Towards rabies elimination in Belgium by fox vaccination using a vaccinia-rabies glycoprotein recombinant virus.

  1994cited by this paper
• A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus.

  1994cited by this paper
• Evaluation of swinepox virus as a vaccine vector in pigs using an Aujeszky's disease (pseudorabies) virus gene insert coding for glycoproteins gp50 and gp63

  1994cited by this paper
• Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules.

  1994cited by this paper
• The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease

  1994cited by this paper
• Protection against turkey rhinotracheitis pneumovirus (TRTV) induced by a fowlpox virus recombinant expressing the TRTV fusion glycoprotein (F).

  1994cited by this paper
• Cell Line-Dependent Release of HIV-Like Gag Particles after Infection of Mammalian Cells with Recombinant Vaccinia Viruses

  1994cited by this paper
• Clinical Trials with VMO for Melanoma

  1993cited by this paper
• Specific Immunotherapy of Cancer With Vaccines

  1993cited by this paper
• Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.

  1993cited by this paper
• Vaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses.

  1993cited by this paper
• A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV.

  1993cited by this paper
• Human trials of experimental AIDS vaccines.

  1993cited by this paper
• Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein.

  1993cited by this paper
• Immunization with Lentivirus-Like Particles Elicits a Potent SIV-Specific Recall Cytotoxic T-Lymphocyte Response in Rhesus Monkeys

  1993cited by this paper
• Immunotherapeutic Strategies for Cancer Using Poxvirus Vectors

  1993cited by this paper
• Expression of the HN, F, NP and M proteins of Sendai virus by recombinant vaccinia viruses and their contribution to protective immunity against Sendai virus infections in mice.

  1993cited by this paper
• Protection of sheep against bovine leukemia virus (BLV) infection by vaccination with recombinant vaccinia viruses expressing BLV envelope glycoproteins: correlation of protection with CD4 T-cell response to gp51 peptide 51-70

  1993cited by this paper
• Immunisation of cattle with a recombinant vaccinia vector expressing the haemagglutinin gene of rinderpest virus

  1993cited by this paper
• Interleukin-12 and its role in the generation of TH1 cells.

  1993cited by this paper
• Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection

  1993cited by this paper
• Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.

  1993cited by this paper
• Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice.

  1993cited by this paper
• Identification of an alternative CTLA-4 ligand costimulatory for T cell activation.

  1993cited by this paper
• Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.

  1993cited by this paper
• Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination.

  1993cited by this paper
• Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL

  1993cited by this paper
• The cytolytic activity of pulmonary CD8+ lymphocytes, induced by infection with a vaccinia virus recombinant expressing the M2 protein of respiratory syncytial virus (RSV), correlates with resistance to RSV infection in mice

  1993cited by this paper
• Safety and Immunogenicity of a Fully Glycosylated Recombinant gp160 Human Immunodeficiency Virus Type 1 Vaccine in Subjects at Low Risk of Infection

  1993cited by this paper
• Protection of goats against peste des petits ruminants with a vaccinia virus double recombinant expressing the F and H genes of rinderpest virus.

  1993cited by this paper
• Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.

  1993cited by this paper
• Single capripoxvirus recombinant vaccine for the protection of cattle against rinderpest and lumpy skin disease.

  1993cited by this paper
• Vaccinia virus recombinants expressing chimeric proteins of human immunodeficiency virus and gamma interferon are attenuated for nude mice.

  1992cited by this paper
• A myxoma virus intergenic transient dominant selection vector.

  1992cited by this paper
• A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine.

  1992cited by this paper
• Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection.

  1992cited by this paper
• Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer.

  1992cited by this paper
• Comparison of the thymidine kinase genes from three entomopoxviruses.

  1992cited by this paper
• Protection of mice and swine from pseudorabies virus conferred by vaccinia virus-based recombinants

  1992cited by this paper
• Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16.

  1992cited by this paper
• Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins.

  1992influential reference
• Protection against Marek's disease by a fowlpox virus recombinant expressing the glycoprotein B of Marek's disease virus

  1992cited by this paper
• Nonreplicating vaccinia vector efficiently expresses recombinant genes.

  1992cited by this paper
• Immunisation with canarypox virus expressing rabies glycoprotein.

  1992cited by this paper
• Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.

  1992cited by this paper
• Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine.

  1992cited by this paper
• Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene

  1992cited by this paper
• Use of Lentivirus-Like Particles Alone and in Combination with Live Vaccinia-Virus-Based Vaccines

  1992cited by this paper
• Development of a live cell culture camelpox vaccine.

  1992cited by this paper
• Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160.

  1992cited by this paper
• Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate.

  1992cited by this paper
• Expression of wild-type and mutant p53 proteins by recombinant vaccinia viruses

  1992cited by this paper
• Construction of vaccinia virus recombinants expressing several measles virus proteins and analysis of their efficacy in vaccination of mice.

  1992cited by this paper
• Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis.

  1992cited by this paper
• Molecular attenuation of vaccinia virus: mutant generation and animal characterization

  1992cited by this paper
• Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy.

  1992cited by this paper
• NYVAC: a highly attenuated strain of vaccinia virus.

  1992influential reference
• A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA)

  1991cited by this paper
• Raccoon poxvirus recombinants expressing the rabies virus nucleoprotein protect mice against lethal rabies virus infection

  1991cited by this paper
• Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine

  1991cited by this paper
• Recombinant vaccinia virus expression of the bovine leukaemia virus envelope gene and protection of immunized sheep against infection.

  1991cited by this paper
• Interleukin 7 induces CD4+ T cell-dependent tumor rejection

  1991cited by this paper
• Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo.

  1991cited by this paper
• Measles virus nucleocapsid protein protects rats from encephalitis

  1991cited by this paper
• Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo

  1991cited by this paper
• Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens.

  1991cited by this paper
• Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7.

  1991cited by this paper
• Protective immunity against bovine leukaemia virus (BLV) induced in carrier sheep by inoculation with a vaccinia virus-BLV env recombinant: association with cell-mediated immunity.

  1991cited by this paper
• Vaccinia virus recombinants expressing either the measles virus fusion or hemagglutinin glycoprotein protect dogs against canine distemper virus challenge

  1991cited by this paper
• Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection.

  1991cited by this paper
• Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen.

  1991cited by this paper
• Immunotherapy and gene therapy of cancer.

  1991cited by this paper
• Efficacy studies on a canarypox-rabies recombinant virus.

  1991influential reference
• Structural proteins of hog cholera virus expressed by vaccinia virus: further characterization and induction of protective immunity

  1991cited by this paper
• Vaccinia recombinants expressing secreted and transmembrane forms of breast cancer-associated epithelial tumour antigen (ETA).

  1991cited by this paper
• Formation of Lentivirus Particles by Mammalian Cells Infected with Recombinant Fowlpox Virus

  1991cited by this paper
• Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus.

  1991cited by this paper
• A vaccinia virus double recombinant expressing the F and H genes of rinderpest virus protects cattle against rinderpest and causes no pock lesions.

  1991cited by this paper
• Swinepox Virus as a Vector for the Delivery of Immunogens

  1991cited by this paper
• Coexpression by vaccinia virus recombinants of equine herpesvirus 1 glycoproteins gp13 and gp14 results in potentiated immunity

  1990cited by this paper
• Primary multiplication site of the vaccinia-rabies glycoprotein recombinant virus administered to foxes by the oral route.

  1990cited by this paper
• Comparison of inactivated, live and recombinant DNA vaccines against influenza virus in a mouse model.

  1990cited by this paper
• Vaccinia recombinants expressing early bovine papilloma virus (BPV1) proteins: retardation of BPV1 tumour development.

  1990cited by this paper
• Induction of protective immunity in animals vaccinated with recombinant vaccinia viruses that express PreM and E glycoproteins of Japanese encephalitis virus

  1990cited by this paper
• A recombinant fowlpox virus expressing the hemagglutinin-neuraminidase gene of Newcastle disease virus (NDV) protects chickens against challenge by NDV.

  1990cited by this paper
• Use of a vaccinia-rabies recombinant virus for the oral vaccination of foxes against rabies.

  1990cited by this paper
• Newcastle disease virus fusion protein expressed in a fowlpox virus recombinant confers protection in chickens

  1990cited by this paper
• Vaccination against tumor cells expressing breast cancer epithelial tumor antigen.

  1990cited by this paper
• Insertion of the fusion gene from Newcastle disease virus into a non-essential region in the terminal repeats of fowlpox virus and demonstration of protective immunity induced by the recombinant.

  1990cited by this paper
• Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2.

  1990cited by this paper
• Immunodeficient mice recover from infection with vaccinia virus expressing interferon‐γ

  1990cited by this paper

• Fowlpox virus: an overview of its classification, morphology and genome, replication mechanisms, uses as vaccine vector and disease dynamics

  2021cites this paper
• The development of gene-based vectors for immunization

  2020cites this paper
• Current status of virus-vectored vaccines against pathogens that affect poultry.

  2020cites this paper
• Major Scientific Hurdles in HIV Vaccine Development: Historical Perspective and Future Directions

  2020cites this paper
• Development of Gene-Based Vectors for Immunization

  2017cites this paper
• Cancer vaccines

  2015cites this paper
• Virological and Immunological Characterization of Novel NYVAC-Based HIV/AIDS Vaccine Candidates Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as Virus-Like Particles

  2014cites this paper
• Attenuated and Replication-Competent Vaccinia Virus Strains M65 and M101 with Distinct Biology and Immunogenicity as Potential Vaccine Candidates against Pathogens

  2013cites this paper
• Deletion of the Vaccinia Virus Gene A46R, Encoding for an Inhibitor of TLR Signalling, Is an Effective Approach to Enhance the Immunogenicity in Mice of the HIV/AIDS Vaccine Candidate NYVAC-C

  2013cites this paper
• Safety and Immunogenicity of Modi fi ed Vaccinia Ankara in Hematopoietic Stem Cell Transplant Recipients: A Randomized, Controlled Trial

  2013cites this paper
• Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.

  2013cites this paper
• A brief history of the global effort to develop a preventive HIV vaccine.

  2013cites this paper
• The Canarypox Virus Vector ALVAC Induces Distinct Cytokine Responses Compared to the Vaccinia Virus-Based Vectors MVA and NYVAC in Rhesus Monkeys

  2013cites this paper
• Safety and Immunogenicity of Modi fi ed Vaccinia Ankara in Hematopoietic Stem Cell Transplant Recipients : A Randomized , Controlled Trial

  2013cites this paper
• Simian Immunodeficiency Virus Epitopes in Subdominant CTL Specific for Dominant and Recombinant Canarypox Vaccine-Elicited

  2013cites this paper
• Prospects for the Therapeutic Use of Anticancer Vaccines

  2012cites this paper
• Delivery of Echinococcus granulosus antigen EG95 to mice and sheep using recombinant vaccinia virus

  2012cites this paper
• NYVAC-C in Mice of the HIV/AIDS Vaccine Candidate Improves Adaptive and Memory Responses Block Interferon Type I and II Pathways Removal of Vaccinia Virus Genes That

  2012cites this paper
• Removal of Vaccinia Virus Genes That Block Interferon Type I and II Pathways Improves Adaptive and Memory Responses of the HIV/AIDS Vaccine Candidate NYVAC-C in Mice

  2012cites this paper
• Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors

  2011cites this paper
• The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in mice.

  2011cites this paper
• Avipoxviruses: infection biology and their use as vaccine vectors

  2011cites this paper
• Targeting OX40 Promotes Lung-Resident Memory CD8 T Cell Populations That Protect against Respiratory Poxvirus Infection

  2011cites this paper
• MVA and NYVAC as vaccines against emergent infectious diseases and cancer.

  2011cites this paper
• Improved Innate and Adaptive Immunostimulation by Genetically Modified HIV-1 Protein Expressing NYVAC Vectors

  2011cites this paper
• OX40:OX40L axis: emerging targets for improving poxvirus‐based CD8+ T‐cell vaccines against respiratory viruses

  2011cites this paper
• Preclinical Qualification of a New Multi-antigen Candidate Vaccine for Metastatic Melanoma

  2010cites this paper
• EVALUATION OF ORAL AND SUBCUTANEOUS DELIVERY OF AN EXPERIMENTAL CANARYPOX RECOMBINANT CANINE DISTEMPER VACCINE IN THE SIBERIAN POLECAT (MUSTELA EVERSMANNI)

  2009cites this paper
• Role of cell signaling in poxvirus-mediated foreign gene expression in mammalian cells.

  2009cites this paper
• Vaccinia virus vaccines: past, present and future.

  2009cites this paper
• JX-594, a targeted oncolytic poxvirus for the treatment of cancer.

  2009cites this paper
• Recombinant vaccines for influenza virus.

  2008cites this paper
• Evaluation of adenoviral vectors

  2008cites this paper
• The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer.

  2008cites this paper
• Preparation of genetically engineered A/H5N1 and A/H7N1 pandemic vaccine viruses by reverse genetics in a mixture of Vero and chicken embryo cells

  2007cites this paper
• Immunotherapy of melanoma: a critical review of current concepts and future strategies

  2007influential citation
• Adapted from: Recent progress in understanding parasite biology, pathology and disease in malaria: translation of knowledge into novel malaria vaccines.

  2007cites this paper
• Investigation of the therapeutic potential of transgenic CD40 ligand expression

  2007cites this paper
• Comparative immunization in BALB/c mice with recombinant replication-defective adenovirus vector and DNA plasmid expressing a SARS-CoV nucleocapsid protein gene.

  2006cites this paper
• The quest for a safe and effective canine distemper virus vaccine for black-footed ferrets

  2006cites this paper
• Enhanced Induction of SARS-CoV Nucleocapsid Protein-Specific Immune Response Using DNA Vaccination followed by Adenovirus Boosting in BALB/c Mice

  2006cites this paper
• Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100

  2006cites this paper
• Nonreplicating Recombinant Vaccinia Virus Expressing CD40 Ligand Enhances APC Capacity to Stimulate Specific CD4+ and CD8+ T Cell Responses

  2005cites this paper
• The cloning and characterization of a profilin homolog encoded by orthopoxviruses

  2005cites this paper
• Enhanced multiepitope-based vaccines elicit CD8+ cytotoxic T cells against both immunodominant and cryptic epitopes.

  2005cites this paper
• Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens.

  2004cites this paper
• Therapeutic cancer vaccines.

  2004cites this paper
• Recombinant viruses obtained from co-infection in vitro with a live vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus display different plaque phenotypes and loss of the transgene.

  2004cites this paper
• Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors

  2004cites this paper
• Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines.

  2003cites this paper
• Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2)

  2003cites this paper
• Chronic Lymphocytic Leukemia-reactive T Cells during Disease Progression and after Autologous Tumor Cell Vaccines 1

  2003cites this paper
• Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques.

  2003cites this paper
• Medical biotechnology in India.

  2003cites this paper
• New approaches in vaccine development.

  2003cites this paper
• Biological response modifiers in cancer therapy.

  2002cites this paper
• Myxoma Virus Leukemia-Associated Protein Is Responsible for Major Histocompatibility Complex Class I and Fas-CD95 Down-Regulation and Defines Scrapins, a New Group of Surface Cellular Receptor Abductor Proteins

  2002cites this paper
• Both Mucosal and Systemic Routes of Immunization with the Live, Attenuated NYVAC/Simian Immunodeficiency Virus SIVgpe Recombinant Vaccine Result in Gag-Specific CD8+ T-Cell Responses in Mucosal Tissues of Macaques

  2002cites this paper
• Containment of Simian Immunodeficiency Virus Infection in Vaccinated Macaques: Correlation with the Magnitude of Virus-Specific Pre- and Postchallenge CD4+ and CD8+ T Cell Responses1

  2002cites this paper
• Adenovirus encoding HIV-1 Vpr activates caspase 9 and induces apoptotic cell death in both p53 positive and negative human tumor cell lines

  2002cites this paper
• Recombinant Canarypox Vaccine-Elicited CTL Specific for Dominant and Subdominant Simian Immunodeficiency Virus Epitopes in Rhesus Monkeys1

  2002cites this paper
• Equivalent immunogenicity of the highly attenuated poxvirus-based ALVAC-SIV and NYVAC-SIV vaccine candidates in SIVmac251-infected macaques.

  2002cites this paper
• Generation of recombinant fowlpox virus using the non-essential F11L orthologue as insertion site and a rapid transient selection strategy.

  2002cites this paper
• ALVAC-SIV-gag-pol-env-Based Vaccination and Macaque Major Histocompatibility Complex Class I (A*01) Delay Simian Immunodeficiency Virus SIVmac-Induced Immunodeficiency

  2002cites this paper
• Design and In Vivo Immunogenicity of a Polyvalent Vaccine Based on SIVmac Regulatory Genes

  2002cites this paper
• Recombinant vaccinia viruses expressing immunoglobulin variable regions efficiently and selectively protect mice against tumoral B-cell growth

  2001cites this paper
• APPLICABILITY OF VACCINIA VIRUS AS CLONING AND EXPRESSION VECTOR FOR BACTERIAL GENES: MICE IMMUNE RESPONSES TO VACCINIA VIRUS EXPRESSING BRUCELLA ABORTUS AND LISTERIA MONOCYTOGENES ANTIGENS

  2001cites this paper
• Prime / Boost Regimen Responses by a DNA-SIV and NYVAC-SIV T Cell + and CD 8 + Virus ( SIV )-Specific CD 4 Potentiation of Simian Immunodeficiency

  2001cites this paper
• Construction and characterization of recombinant vaccinia viruses co-expressing a respiratory syncytial virus protein and a cytokine.

  2001cites this paper
• Recombinant proteins produced by vaccinia virus vectors can be incorporated within the virion (IMV form) into different compartments

  2001cites this paper
• Therapeutic vaccines against melanoma and colorectal cancer.

  2001cites this paper
• Potentiation of Simian Immunodeficiency Virus (SIV)-Specific CD4+ and CD8+ T Cell Responses by a DNA-SIV and NYVAC-SIV Prime/Boost Regimen

  2001cites this paper
• Construction and immunogenicity prediction of Plasmodiumfalciparum CTL epitope minigene vaccine

  2001cites this paper
• ALVAC-mediated gene transfer is efficient in lymphoid malignancies of T-and early B-cell origin, but not in tumors arising from mature B-cells

  2001cites this paper
• Developments in preclinical AIDS vaccine efficacy models.

  2000cites this paper
• Use of a mouse lung challenge model to identify antigens protective against Chlamydia pneumoniae lung infection.

  2000cites this paper
• Recombinant viruses as a tool for therapeutic vaccination against human cancers.

  2000cites this paper
• Antitumor vaccination: where we stand.

  2000cites this paper
• Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule

  2000cites this paper
• Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes.

  2000cites this paper
• Poxvirus as a vector to transduce human dendritic cells for immunotherapy: abortive infection but reduced APC function

  2000cites this paper
• Gene vectors for cytokine expression in vivo.

  2000cites this paper
• Production and delivery of recombinant subunit vaccines

  2000cites this paper
• Comparative Efficacy of Recombinant Modified Vaccinia Virus Ankara Expressing Simian Immunodeficiency Virus (SIV) Gag-Pol and/or Env in Macaques Challenged with Pathogenic SIV

  2000cites this paper
• HIV-1 Env in a Dose-Dependent Manner the Cellular Immune Response Against Virus Attenuates the Vector and Enhances IL-12 Delivery from Recombinant Vaccinia Zavala and

  1999cites this paper
• Recombinant vaccinia viruses

  1999cites this paper
• Effect of virulence on immunogenicity of single and double vaccinia virus recombinants expressing differently immunogenic antigens: antibody-response inhibition induced by immunization with a mixture of recombinants differing in virulence.

  1999cites this paper
• IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner.

  1999cites this paper
• Two-Helper RNA System for Production of Recombinant Semliki Forest Virus Particles

  1999cites this paper
• Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera.

  1999cites this paper
• [A balance of clinical trials in gene therapy].

  1999cites this paper
• The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation.

  1999cites this paper
• Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines.

  1999cites this paper
• New approaches in vaccine development.

  1998cites this paper
• An Experimental Prime–Boost Regimen Leading to HIV Type 1-Specific Mucosal and Systemic Immunity in BALB/c Mice

  1998cites this paper
• Naturally Occurring Orthopoxviruses: Potential for Recombination with Vaccine Vectors

  1998cites this paper
• [Gene therapy: a review 6 years after the first trials in man. Round Table No 6 at Giens XIII].

  1998cites this paper
• Induction of Melanoma Antigen‐Specific Cytotoxic T Lymphocytes In Vitro by Stimulation with B7‐Expressing Human Melanoma Cell Lines

  1998cites this paper
• Characteristics of four cowpox virus isolates from Norway and Sweden

  1998cites this paper
• Recombinant Vaccine-Induced Protection against the Highly Pathogenic Simian Immunodeficiency Virus SIVmac251: Dependence on Route of Challenge Exposure

  1998cites this paper